CENTESSA PHARMACEUTICALS (F:260) — Market Cap & Net Worth
Market Cap & Net Worth: CENTESSA PHARMACEUTICALS (260)
CENTESSA PHARMACEUTICALS (F:260) has a market capitalization of $5.35 Billion (€4.58 Billion) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #3417 globally and #640 in its home market, demonstrating a 2.98% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CENTESSA PHARMACEUTICALS's stock price €34.60 by its total outstanding shares 154731309 (154.73 Million). Also see CENTESSA PHARMACEUTICALS total assets for a full breakdown of the balance sheet.
CENTESSA PHARMACEUTICALS Market Cap History: 2021 to 2026
CENTESSA PHARMACEUTICALS's market capitalization history from 2021 to 2026. Data shows growth from $1.78 Billion to $6.26 Billion (14.05% CAGR). Also see 260 cash flow conversion for how efficiently the company converts equity into cash flow.
CENTESSA PHARMACEUTICALS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CENTESSA PHARMACEUTICALS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 260 stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
180.90x
CENTESSA PHARMACEUTICALS's market cap is 180.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $1.26 Billion | $6.85 Million | -$151.09 Million | 183.46x | N/A |
| 2025 | $2.71 Billion | $15.00 Million | -$197.53 Million | 180.90x | N/A |
Competitor Companies of 260 by Market Capitalization
Companies near CENTESSA PHARMACEUTICALS in the global market cap rankings as of September 19, 2026. Review 260 intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to CENTESSA PHARMACEUTICALS by market ranking:
- Oberbank AG (VI:OBS): Ranked #3408 globally with a market cap of $5.38 Billion USD ( €4.60 Billion EUR).
- TPG Telecom Ltd (AU:TPG): Ranked #3409 globally with a market cap of $5.38 Billion USD ( AU$7.60 Billion AUD).
- Silergy Corp (TW:6415): Ranked #3418 globally with a market cap of $5.35 Billion USD ( NT$169.90 Billion TWD).
- Tianfeng Securities Co Ltd (SHG:601162): Ranked #3419 globally with a market cap of $5.35 Billion USD ( CN¥36.57 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #3408 | Oberbank AG | VI:OBS | $5.38 Billion | €83.60 |
| #3409 | TPG Telecom Ltd | AU:TPG | $5.38 Billion | AU$3.87 |
| #3418 | Silergy Corp | TW:6415 | $5.35 Billion | NT$437.50 |
| #3419 | Tianfeng Securities Co Ltd | SHG:601162 | $5.35 Billion | CN¥3.63 |
CENTESSA PHARMACEUTICALS Historical Marketcap From 2021 to 2026
Between 2021 and today, CENTESSA PHARMACEUTICALS's market cap moved from $1.78 Billion to $ 6.26 Billion, with a yearly change of 14.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €6.26 Billion | +130.67% |
| 2025 | €2.71 Billion | -3.85% |
| 2024 | €2.82 Billion | +124.46% |
| 2023 | €1.26 Billion | +139.66% |
| 2022 | €524.60 Million | -70.56% |
| 2021 | €1.78 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of CENTESSA PHARMACEUTICALS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.35 Billion USD |
| MoneyControl | $5.35 Billion USD |
| MarketWatch | $5.35 Billion USD |
| marketcap.company | $5.35 Billion USD |
| Reuters | $5.35 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CENTESSA PHARMACEUTICALS
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hyperso… Read more